

Supplementary Information

Solid Tumor Treatment via Augmentation of Bioactive C6 Ceramide Levels with Thermally Ablative Focused Ultrasound

**E. Andrew Thim¹, Todd Fox², Tye Deering², Luke R. Vass³, Natasha D. Sheybani¹,
Mark Kester^{1,2}, and Richard J. Price^{1,*}**

1. Department of Biomedical Engineering, University of Virginia, Charlottesville, VA 22908

2. Department of Pharmacology, University of Virginia, Charlottesville, VA 22908

3. Department of Pathology, University of Virginia, Charlottesville, VA 22908

*Corresponding Author:

Richard J. Price, Ph.D.
Department of Biomedical Engineering
Box 800759, Health System
University of Virginia
Charlottesville, VA 22908, USA
Telephone: (434) 924-0020
Email: rprice@virginia.edu
ORCID: 0000-0002-0237-2102




Fig. S1 Treatment scheme for TA of 4T1 tumors. Biorender.com




Fig. S2 C6-ceramide levels through time after TA+CNL treatment. CNLs were injected immediately prior to Sham or TA treatment. Tumors and serum were harvested 15 minutes (n=5-6), 2 hrs (n=4), 7.5 hrs (n=4-6) and 24 hrs (n=3-5) post treatment. a. Bioactive C6-ceramide levels. b. Levels of C6-ceramide metabolized into sphingomyelin. c. Levels of C6-ceramide metabolized into hexosyl-ceramides. d. Total C6-ceramide levels. e. Bioactive C6-ceramide levels in serum.




Fig. S3 Absolute ceramide metabolite levels 24 hrs after Sham or TA treatment in combination with GNL and CNL injection. Long-chain ceramides (A-C) are C14, C16 and C18. Very-long-chain ceramides (D-E) are C24 and C26. For all data sets: n=7-9 and **p<0.01, ***p<0.001.